Akston Biosciences Announces Positive Interim Phase II Results from COVID “Universal” Booster Vaccine Trial

BEVERLY, Mass.--(BUSINESS WIRE)-- #VIE--Akston announced topline results: Phase II COVID booster trial found 93% of previously vaccinated subjects had increased neutralizing antibody titers.